NIH launches clinical trials of COVID-19 blood-clotting treatments
The National Institutes of Health yesterday announced the launch of two of three planned, worldwide phase 3 clinical trials of varying types of blood thinners to treat adults with COVID-19.
Trials will include hospitalized and non-hospitalized patients; the expected third trial will later focus on those discharged after hospitalization for moderate-to-severe disease.
NIH said research shows many COVID-19 patients who died suffered from blood clots throughout their bodies; these blood thinners, known as ACTIV-4 antithrombotics, could provide insights for care.
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…